CTLA4 and acute myeloid leukemia: In recent years, with the rapid development of CTLA-4, PD-1, and other immune checkpoint therapies used in AML, such as immune cells, extracellular matrix molecules, and stromal cells as critical cells in TME are getting more and more attention [50].